Growth momentum Diligent Pharma has secured Series A funding of $8.27M in mid-2023, signaling capital availability and growth plans. This presents an opening to position enhanced vendor qualification and risk management across more sponsors and larger clinical programs.

Platform value The company operates a secure platform that streamlines vendor discovery, qualification, and management to shorten study start-up and improve quality. This creates opportunities to upsell expanded risk intelligence, audit-ready documentation, and broader sponsor-vendor collaboration features.

Quality and compliance With emphasis on accredited audit reports, pre-completed RFIs, and international regulatory compliance, there is potential to target sponsors seeking faster vendor onboarding and reduced qualification fatigue across multi-country trials.

SME credibility Built by clinical trial subject-matter experts and already used by large industry players, Diligent Pharma can leverage their domain expertise to cross-sell to mid-market sponsors looking for robust, compliant vendor ecosystems.

Market alignment The focus on risk management and efficiency aligns with current industry pressures to de-risk CRO/Vendor networks and accelerate trial timelines, presenting a clear value proposition for sponsors facing tight trial start-up windows.